Porton Pharma Solutions Future Growth

Future criteria checks 5/6

Porton Pharma Solutions is forecast to grow earnings and revenue by 103.3% and 26.5% per annum respectively while EPS is expected to grow by 103.2% per annum.

Key information

103.3%

Earnings growth rate

103.2%

EPS growth rate

Pharmaceuticals earnings growth	18.6%
Revenue growth rate	26.5%
Future return on equity	n/a
Analyst coverage	Good
Last updated	13 Mar 2024

Recent future growth updates

Recent updates

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Mar 26

Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Mar 04

Earnings and Revenue Growth Forecasts

SZSE:300363 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	4,783	606	N/A	967	8
12/31/2024	3,884	445	N/A	897	8
3/31/2024	2,967	-132	-650	347	N/A
12/31/2023	3,667	267	-501	629	N/A
9/30/2023	4,854	880	-15	1,199	N/A
6/30/2023	5,460	1,203	1,709	2,876	N/A
3/31/2023	6,970	1,928	1,359	2,593	N/A
1/1/2023	7,035	2,005	1,391	2,564	N/A
9/30/2022	6,293	1,741	1,325	2,533	N/A
6/30/2022	5,763	1,522	-299	850	N/A
3/31/2022	4,005	818	-103	779	N/A
1/1/2022	3,105	524	-297	480	N/A
9/30/2021	2,614	446	-146	415	N/A
6/30/2021	2,402	408	14	487	N/A
3/31/2021	2,224	364	-46	439	N/A
12/31/2020	2,072	324	110	504	N/A
9/30/2020	1,958	289	177	524	N/A
6/30/2020	1,852	251	189	400	N/A
3/31/2020	1,689	217	240	441	N/A
12/31/2019	1,551	186	176	351	N/A
9/30/2019	1,430	163	148	290	N/A
6/30/2019	1,299	159	182	337	N/A
3/31/2019	1,225	119	40	174	N/A
12/31/2018	1,185	124	25	194	N/A
9/30/2018	1,191	134	6	163	N/A
6/30/2018	1,101	79	-182	-20	N/A
3/31/2018	1,039	73	11	170	N/A
12/31/2017	1,184	107	N/A	291	N/A
9/30/2017	1,242	121	N/A	276	N/A
6/30/2017	1,307	138	N/A	458	N/A
3/31/2017	1,399	182	N/A	398	N/A
12/31/2016	1,327	171	N/A	285	N/A
9/30/2016	1,194	148	N/A	183	N/A
6/30/2016	1,097	148	N/A	74	N/A
3/31/2016	1,029	125	N/A	-14	N/A
12/31/2015	1,021	110	N/A	112	N/A
9/30/2015	1,155	142	N/A	349	N/A
6/30/2015	1,156	138	N/A	316	N/A
3/31/2015	1,072	127	N/A	304	N/A
12/31/2014	987	125	N/A	122	N/A
9/30/2014	719	71	N/A	-90	N/A
6/30/2014	739	88	N/A	-9	N/A
3/31/2014	723	90	N/A	42	N/A
12/31/2013	734	100	N/A	114	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300363 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).

Earnings vs Market: 300363 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 300363 is expected to become profitable in the next 3 years.

Revenue vs Market: 300363's revenue (26.5% per year) is forecast to grow faster than the CN market (14.7% per year).

High Growth Revenue: 300363's revenue (26.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 300363's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Porton Pharma Solutions Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Price target decreased by 11% to CN¥33.00

Consensus EPS estimates increase by 12%

Consensus EPS estimates increase by 12%

Consensus EPS estimates fall by 10%

Price target decreased by 9.8% to CN¥37.00

Consensus EPS estimates fall by 43%, revenue upgraded

Recent updates

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: CN¥0.17 loss per share (vs CN¥0.56 profit in 1Q 2023)

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

Porton Pharma Solutions Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Investor sentiment deteriorates as stock falls 15%

Porton Pharma Solutions Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Price target decreased by 11% to CN¥33.00

Consensus EPS estimates increase by 12%

Consensus EPS estimates increase by 12%

Consensus EPS estimates fall by 10%

New major risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.075 (vs CN¥0.67 in 3Q 2022)

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 19%

Price target decreased by 9.8% to CN¥37.00

Consensus EPS estimates fall by 43%, revenue upgraded

Second quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥1.53 in 2Q 2022)

Porton Pharma Solutions Ltd. to Report First Half, 2023 Results on Aug 19, 2023

Upcoming dividend of CN¥1.11 per share at 3.2% yield

Consensus EPS estimates fall by 26%

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 8.7% to CN¥70.63

Investor sentiment improved over the past week

High number of new directors

Consensus revenue estimates fall by 11%

Third quarter 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Consensus EPS estimates increase by 21%

Price target decreased to CN¥104

Second quarter 2022 earnings released: EPS: CN¥1.53 (vs CN¥0.23 in 2Q 2021)

Porton Pharma Solutions Ltd. (SZSE:300363) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

High number of new directors

High number of new and inexperienced directors

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Porton Pharma Solutions Ltd. Announces Final Dividend for 2021, Payable on 28 April 2022

Porton Pharma Solutions Ltd. Approves Cash Dividend for 2021

Consensus revenue estimates increase by 52%

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.20 in 3Q 2020)

Porton Pharma Solutions Ltd. (SZSE:300363) agreed to acquire 70% stake in Hubei Yuyang Pharmaceutical Co., Ltd. from a group of shareholders for approximately CNY 170 million.

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.16 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.09 in 1Q 2020)

Porton Pharma Solutions Ltd. Announces on 15 March 2021 the Profit Distribution Proposal for 2020

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 06, 2021

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.35 in FY 2019)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.35 in FY 2019)

Revenue beats expectations

New 90-day high: CN¥46.67

Zhangjiagang Zhuoyuan Investment Partnership (Limited Partnership) completed the acquisition of 5.24% stake in Porton Pharma Solutions Ltd. (SZSE:300363) from Ju Nianfeng, Tao Rong, and Zhang Hebing.

Porton Pharma Solutions Ltd. to Report Fiscal Year 2020 Results on Mar 13, 2021

New 90-day high: CN¥42.13

Investor sentiment improved over the past week

Analysts update estimates

New 90-day high: CN¥39.66

Third quarter earnings released

Porton Pharma Solutions Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Market bids up stock over the past week

New 90-day high: CN¥38.90

Porton Pharma Solutions Ltd. Announces Board Changes

Earnings released

Porton Pharma Solutions Ltd. to Report First Half, 2020 Results on Aug 20, 2020